TY - JOUR
T1 - Effect of antihypertensive treatment on 24-h blood pressure variability
T2 - Pooled individual data analysis of ambulatory blood pressuremonitoring studies based on olmesartan mono or combination treatment
AU - Omboni, Stefano
AU - Kario, Kazuomi
AU - Bakris, George
AU - Parati, Gianfranco
N1 - Publisher Copyright:
© 2018 the Author.
PY - 2018/4
Y1 - 2018/4
N2 - Objective: To evaluate the impact of olmesartan alone or combined with one to three antihypertensive drugs on 24-h blood pressure variability (BPV) and on distribution of BP reduction in a pooled individual data analysis of 10 doubleblind, randomized, ambulatory BP monitoring (ABPM) studies. Methods: ABPMs were performed before and after 6-12 weeks of treatment with placebo (n=119), active control monotherapy [n=1195, angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), dihydropyridine calcium channel blockers (DCCBs)] olmesartan monotherapy (n=1410), active control dual combination [n=79, DCCBRthiazide diuretic (TD)], olmesartan dual combination (n=637, DCCB or TD), and triple combination therapy (n=102, DCCBRTD). 24-h BPV was calculated as unweighted or weighted SD of the mean BP, and average real variability. BP control was assessed by smoothness index and treatment-on-variability index. Results: The greatest effect on 24-h systolic BPV/diastolic BPV was observed under olmesartan triple [-2.6/-1.9;-1.9/-1.3;-1.4/-1.3mmHg] and active control dual combination [-1.8/-1.4;-1.9/-1.5; 1.2/1.1 mmHg]. Smoothness indexes and treatment-on-variability indexes were significantly (P=0.0001) higher under olmesartan dual (1.53/1.22, 1.67/1.29, 2.05/1.59), olmesartan triple (2.47/1.85, 2.80/2.06, 3.64/2.67), or active control dual combination (1.70/1.26, 1.85/1.33, 2.29/1.65) than under monotherapies (control: 0.86/0.73, 0.80/0.65, 1.01/0.82; olmesartan: 1.02/0.86, 0.95/0.78, 1.23/1.00). They were also greater in patients receiving high-dose olmesartan monotherapy or high-dose olmesartan dual combination than in the corresponding low-dose group. Conclusion: Olmesartan plus a DCCB and/or a TD produces a larger, more sustained, and smoother BP reduction than placebo and monotherapies, a desirable feature for a more effective prevention of the cardiovascular consequences of uncontrolled hypertension. Keywords: Ambulatory blood pressure monitoring, arterial hypertension, blood pressure, blood pressure variability, olmesartan, smoothness index, treatment-on-variability index. sTrough-To-peak Ratio.
AB - Objective: To evaluate the impact of olmesartan alone or combined with one to three antihypertensive drugs on 24-h blood pressure variability (BPV) and on distribution of BP reduction in a pooled individual data analysis of 10 doubleblind, randomized, ambulatory BP monitoring (ABPM) studies. Methods: ABPMs were performed before and after 6-12 weeks of treatment with placebo (n=119), active control monotherapy [n=1195, angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), dihydropyridine calcium channel blockers (DCCBs)] olmesartan monotherapy (n=1410), active control dual combination [n=79, DCCBRthiazide diuretic (TD)], olmesartan dual combination (n=637, DCCB or TD), and triple combination therapy (n=102, DCCBRTD). 24-h BPV was calculated as unweighted or weighted SD of the mean BP, and average real variability. BP control was assessed by smoothness index and treatment-on-variability index. Results: The greatest effect on 24-h systolic BPV/diastolic BPV was observed under olmesartan triple [-2.6/-1.9;-1.9/-1.3;-1.4/-1.3mmHg] and active control dual combination [-1.8/-1.4;-1.9/-1.5; 1.2/1.1 mmHg]. Smoothness indexes and treatment-on-variability indexes were significantly (P=0.0001) higher under olmesartan dual (1.53/1.22, 1.67/1.29, 2.05/1.59), olmesartan triple (2.47/1.85, 2.80/2.06, 3.64/2.67), or active control dual combination (1.70/1.26, 1.85/1.33, 2.29/1.65) than under monotherapies (control: 0.86/0.73, 0.80/0.65, 1.01/0.82; olmesartan: 1.02/0.86, 0.95/0.78, 1.23/1.00). They were also greater in patients receiving high-dose olmesartan monotherapy or high-dose olmesartan dual combination than in the corresponding low-dose group. Conclusion: Olmesartan plus a DCCB and/or a TD produces a larger, more sustained, and smoother BP reduction than placebo and monotherapies, a desirable feature for a more effective prevention of the cardiovascular consequences of uncontrolled hypertension. Keywords: Ambulatory blood pressure monitoring, arterial hypertension, blood pressure, blood pressure variability, olmesartan, smoothness index, treatment-on-variability index. sTrough-To-peak Ratio.
UR - http://www.scopus.com/inward/record.url?scp=85051665801&partnerID=8YFLogxK
U2 - 10.1097/HJH.0000000000001608
DO - 10.1097/HJH.0000000000001608
M3 - Review article
C2 - 29045341
AN - SCOPUS:85051665801
SN - 0263-6352
VL - 36
SP - 720
EP - 733
JO - Journal of Hypertension
JF - Journal of Hypertension
IS - 4
ER -